Antiviral compound could be broadly efficient in the treatment of SARS-CoV-2
A new study led by Gonçalo Bernardes, group leader at the Instituto de Medicina Molecular João Lobo Antunes (iMM; Portugal) and Professor at the University of Cambridge (Cambridge, UK), and published recently in the scientific journal ACS Central Science* reports the discovery of a compound efficient in the treatment of SARS-CoV-2 that could be broadly applied to treat different variants of the virus.
The researchers discovered that the compound piperlongumine (PL), extracted from the long pepper, the most extensively natural ingredient used in Indian medical systems, has a potent antiviral effect in the treatment of SARS-CoV-2 in mice.
“We found that PL delays disease progression and reduces lung inflammation in a mouse model mimicking SARS-CoV-2 infection”, says Gonçalo Bernardes, leader of the study. “The action of this compound in the organism, which was previously studied in the treatment of cancer, is the induction of a stress response in the host cells. In our work, we saw that this stress response is selective for infected cells. This is quite advantageous because PL acts on the cells infected by the virus and not on the virus itself, making it a potential antiviral treatment that can be efficient in upcoming variants of SARS-CoV-2 or even different viruses, to fight future outbreaks”, continues to explain Gonçalo Bernardes. The researchers tested PL treatment in mice infected with alpha, delta and omicron variants of SARS-CoV-2 and the treatment is efficient in decreasing the amount of virus in the three different variants.
To access the relevance of the compound as a potential treatment, the effect of PL was compared with Plitidepsin, an antiviral administered subcutaneously that is already known to reduce viral load in SARS-CoV-2 infection. “In the case of PL we were able to administer intranasally, which was suggested as a better route because the nasal mucosa is frequently the primary site of infection in SARS-CoV-2. We demonstrated that PL intranasal administration is not toxic and the treatment is more effective in the infected mice relative to Plitidepsin, a potent antiviral that is currently being tested in human clinical trials”, adds Cong Tang, first author of the study.
Although the discovery of vaccines contributed significantly to the control of the SARS-CoV-2 pandemic, it is essential to find and develop treatments specially since the virus continues to adapt to the new human host overtime. The compound studied in this work, PL, can be particularly relevant as an antiviral since it exerts its antiviral action by affecting the host cells, instead of the virus. This makes PL a great candidate to be used in upcoming variants of SARS-CoV-2 and even other viruses.
This work was developed at iMM (Portugal) in collaboration with the University of Cambridge (UK) and the Champalimaud Foundation (Portugal). This study was funded by the Marie Skłodowska-Curie grant (Agreement No. 101038053) from the European Union’s Horizon 2020 research and innovation program.
*Cong Tang, Ana R. Coelho, Maria Rebelo, Hannah Kiely-Collins, Tânia Carvalho, and Gonçalo J. L. Bernardes. 2023. A Selective SARS-CoV‑2 Host-Directed Antiviral Targeting Stress Response to Reactive Oxygen Species. ACS Central Science. DOI: 10.1021/acscentsci.2c01243
ACS Central Science
Method of Research
Subject of Research
A Selective SARS-CoV‑2 Host-Directed Antiviral Targeting Stress Response to Reactive Oxygen Species.
Article Publication Date
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.